CORT
NASDAQ
US
Corcept Therapeutics Incorporated - Common Stock
$42,49
▲ +$0,51
(+1,21%)
Vol. 1.5M
11
Punteggio di Qualità
ok
Analisi approfondita
2/5
ok
Ricavi ✓
Utile netto ✓
>IPO ✗
Cap. mercato
$3.7B
P/E
34,5
ROE
16,1%
Margine
14,3%
D/E
0,00
Beta
0,18
52W
$49–$117
Consenso Wall Street
12 analisti · Apr 20262
Acquisto forte
7
Compra
3
Mantieni
0
Vendi
0
Vendita forte
75,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
AXSM
Axsome Therapeutics Inc
$9.2B
BLTE
Belite Bio Inc
$5.6B
TERN
Terns Pharmaceuticals Inc
$4.3B
LGND
Ligand Pharmaceuticals Inc
P/E 76,6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671,4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35,8
$4.5B
GPCR
Structure Therapeutics Inc
$4.2B
EWTX
Edgewise Therapeutics Inc
$2.6B
Utili
Tasso di battuta: 75,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $0,31 | $0,20 | $-0,11 |
| Set 2025 | $0,14 | $0,16 | +$0,02 |
| Giu 2025 | $0,19 | $0,29 | +$0,10 |
| Mar 2025 | $0,15 | $0,17 | +$0,02 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $181.9M | $157.2M | $194.4M | $207.6M | $202.1M |
| Utile netto | — | $30.7M | $20.5M | $35.1M | $19.7M | $24.3M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 20.3% | 20.3% | 20.3% | 20.3% | 16.1% | 16.1% |
| P/E (TTM) | 58.24 | 55.72 | 67.13 | 57.92 | 78.80 | 34.50 |
| Net Margin | 18.1% | 18.7% | 18.7% | 18.7% | 14.3% | 14.3% |
| Gross Margin | 98.2% | 98.4% | 98.4% | 98.4% | 98.2% | 98.2% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.06 | 3.06 | 3.06 | 3.06 | 3.14 | 3.14 |
Rapporti chiave
ROA (TTM)
12,8%
P/S (TTM)
4,94
P/B
7,8
EPS (TTM)
$0,89
CF/Share
$0,81
Crescita ricavi 3A
+22,6%
52W High
$117,33
52W Low
$49,00
$49,00
Intervallo 52 settimane
$117,33
Salute finanziaria
Flusso di cassa libero
$38.4M
Debito netto
-$114.4M
Liquidità
$120.5M
Debito totale
$6.1M
Aggiornato al Dic 31, 2025
Як CORT виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Mid-cap Pharmaceuticals ($2B+) · 25 компаній
Оцінка CORT vs аналоги Pharmaceuticals
P/E
34,5
▲
13%
sopra
peer
(30,7)
vs Peer
vs Settore
Sottovalutato
P/S
4,9
▼
27%
sotto
peer
(6,7)
vs Peer
vs Settore
Più costoso
P/B
7,8
▲
49%
sopra
peer
(5,2)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(3,1%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CORT vs аналоги Pharmaceuticals
ROE
16,1%
▲
162%
sopra
peer
(-26,1%)
vs Peer
vs Settore
Top livello
Net margin
14,3%
▲
1088%
sopra
peer
(-1,5%)
vs Peer
vs Settore
Sotto media
Валова маржа
98,2%
▲
10%
sopra
peer
(88,9%)
vs Peer
vs Settore
In linea
ROA
12,8%
▲
236%
sopra
peer
(-9,5%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя CORT vs аналоги Pharmaceuticals
D/E ratio
0,0
▼
100%
sotto
peer
(27,4)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
3,1
▼
10%
sotto
peer
(3,5)
vs Peer
vs Settore
In linea
Beta
0,2
▼
70%
sotto
peer
(0,6)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CORT
CORT
Mediana peer
Industria
CORT прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CORT vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
BELANOFF JOSEPH K
Chief Executive Officer · Mar 25
26198 shs
GUYER WILLIAM
Officer · Mar 20
11767 shs
GUYER WILLIAM
Officer · Mar 20
11767 shs
WILSON JAMES N
Director · Mar 20
4000 shs
BAKER GEORGE LEONARD JR.
Director · Mar 17
100000 shs
MAHONEY DAVID L
Director · Mar 13
30000 shs
WILSON JAMES N
Director · Mar 13
28000 shs
MAHONEY DAVID L
Director · Mar 13
24531 shs
GUYER WILLIAM
Officer · Mar 04
8233 shs
GUYER WILLIAM
Officer · Mar 04
8233 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 36,09%Blackrock Inc.
11,34%
$453.5M
Vanguard Group Inc
8,93%
$357.0M
Ingalls & Snyder LLC
6,76%
$270.5M
Renaissance Technologies, L…
5,41%
$216.5M
Parallel Advisors, LLC
3,65%
$145.9M
Aggiornato al Dic 31, 2025